Category

• Pipeline2
• Research1

Organizations

• Bausch + Lomb64
• Eyes On Eyecare42
• Alcon, Inc.41
• American Optometric Association34
• Harrow26
• Glaukos25
• Regeneron21
• Aldeyra Therapeutics20
• Sight Sciences19
• American Academy Of Ophthalmology18

Tags

• AMD1
• Dry Eye1
• Dry Eye Disease1
• Glaucoma1
• Inherited Retinal Disease1
• Licensing Agreement1
• Retinitis Pigmentosa1

• Organizations: Théa Open Innovation✕

Clear all

Pipeline

Théa acquires exclusive rights to Kiora's IRD therapy

Commercialization agreement involves clinical development of KIO-301 for retinitis pigmentosa.

Pipeline

Théa Open Innovation, Link Biologics partner on DED drug

Biologic-based Link_TSG6 has been found to accelerate corneal wound healing, increase tear production, and reduce inflammation.

Research

Théa Open Innovation, Galimedix collaborate for GAL-101 development and commercialization

Novel treatment for dry AMD and glaucoma aims to provide neuroprotection and improved visual function.